TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/24/2024
Back to search
Official data from USPTO
OCULAR THERAPEUTIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
05/24/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
05/09/2022
Registration date
05/21/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/21/2024
Last transaction
05/24/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
First use anywhere
2009-09-00
First use in commerce
2009-09-00
Drawing code
3
Owner type
03
Owner location
Bedford, MA, US
Examiner
DOMBROW, COLLEEN
Law office
L10
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the word "OCULAR" in a stylized font with a larger, stylized letter "O", which is positioned above a horizontal line, and the stylized word "THERAPEUTIX" in a stylized font, which is positioned below the horizontal line. A shaded diamond forms the dot above the lower case letter "I" in the word "THERAPEUTIX".
Holders and representatives
Holders
OCULAR THERAPEUTIX, INC.
Representatives
Matthew P. Hintz, Esq. Lowenstein Sandler, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals for treatment of ophthalmic diseases and conditions; Ophthalmic preparations; Pharmaceutical preparations for the treatment of eye diseases and conditions; Medical inserts namelyimplantable intravitreal drug delivery devices sold filled with ophthalmic pharmaceutical preparations for treating glaucomadry eye diseasemacular degenerationlowering intraocular pressure; Pharmaceutical preparations for the treatment of glaucomadry eye diseasemacular degeneration; Pharmaceutical preparations for the treatment of lowering intraocular pressure; Medical insertimplantable intravitreal drug delivery devices sold filled with pharmaceutical preparations in the nature of dexamethasone for the treatment of eye diseases and conditions; Medical insertimplantable intravitreal drug delivery devices sold filled with pharmaceutical preparations in the nature of dexamethasone for post-op pain and inflammation of the eyeitching associated with allergic conjunctivitis
Class 42
Research and development in the pharmaceutical and biopharmaceutical fields; Development of pharmaceutical and biopharmaceutical preparationsinsertsimplantsmedicines; Pharmaceutical and biopharmaceutical products development
Publications
History of USPTO decisions and trademark events.
34 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/24/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/24/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/24/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/24/2024
NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/21/2024
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
05/21/2024
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
04/15/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/03/2024
GNRT
NON-FINAL ACTION E-MAILED
04/03/2024
CNRT
NON-FINAL ACTION WRITTEN
04/03/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/06/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/06/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/04/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/06/2023
GNRT
NON-FINAL ACTION E-MAILED
12/06/2023
CNRT
NON-FINAL ACTION WRITTEN
12/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/05/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/05/2023
ALIE
ASSIGNED TO LIE
11/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/02/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/02/2022
GNRT
NON-FINAL ACTION E-MAILED
12/02/2022
CNRT
NON-FINAL ACTION WRITTEN
12/02/2022
DOCK
ASSIGNED TO EXAMINER
11/30/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/10/2022
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
05/17/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/16/2022
NWAP
NEW APPLICATION ENTERED
05/12/2022
Continuous trademark protection
Get notified about every new filing that threatens OCULAR THERAPEUTIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.